FreeStyle Libre Flash Accuracy Study

• ClinicalTrials.gov Identifier: NCT03257501
• Recruitment Status: Completed
• First Posted: August 22, 2017
• Last Update Posted: January 9, 2018
• Sponsor: Abbott Diabetes Care
• Information provided by (Responsible Party): Abbott Diabetes Care

Study Description

Brief Summary:

This is a non-randomized, single arm, multi-center, prospective, non-significant risk study to evaluate the FreeStyle Libre Flash Glucose Monitoring System.

Condition or disease	Intervention/treatment
Diabetes Mellitus	Device: FreeStyle Libre Flash Glucose Monitoring System

Detailed Description:

Up to 150 subjects will be enrolled at four (4) clinical research sites in the United States. Subjects will wear two Sensors of three unique sensor lots. Each Sensor will have a paired Reader that will be given to the subject. All Readers will be masked during the study (i.e. subjects will not be able to view glucose results obtained from the Sensor on the Reader screen). Subjects will be asked to perform at least 8 capillary Blood Glucose (BG) tests per day using the primary Reader. Interstitial glucose readings from each Sensor will be obtained with the corresponding Readers immediately following each BG test. Subjects will be instructed to report any problems with the device. Subjects will make eight (8) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1). Subjects will have five (5) in-clinic visits during which intravenous blood draws and YSI reference testing will occur.

Study Design

• Study Type: Observational
• Actual Enrollment: 104 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
• Actual Study Start Date: August 22, 2017
• Actual Primary Completion Date: January 8, 2018
• Actual Study Completion Date: January 8, 2018

Groups and Cohorts

Intervention Details:

• Device: FreeStyle Libre Flash Glucose Monitoring System
  Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.

Outcome Measures

Primary Outcome Measures :

1. System Performance with respect to YSI reference venous plasma sample measurements. [ Time Frame: Approximately 35 hours ]
   System performance will be characterized with respect to YSI reference venous plasma sample measurements.
2. System Related adverse device effects [ Time Frame: Up to 51 days ]
   System will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Subjects with type 1 or type 2 diabetes requiring multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII).

Criteria

Inclusion Criteria:

• Subject must be at least 18 years of age.
• Subject must have type 1 or type 2 diabetes.
• Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
• Willing to perform a minimum of 8 finger sticks per day during the study.
• Subject must be willing to fast five individual times prior to in-clinic visits, each fast lasting a minimum of eight hours.
• Subject must be able to read and understand English.
• In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
• Subject must be available to participate in all study visits.
• Subject must be willing and able to provide written signed and dated informed consent.

Exclusion Criteria:

• Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
• Subject is pregnant, attempting to conceive or not willing and able to practice birth control during the study duration (applicable to female subjects only).
• Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
• Subject is currently participating in another clinical trial.
• Subject has donated blood within 112 days (3.7 months) prior to the beginning of the study activities.
• Subject is anemic as determined by the Investigator.
• Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff. Such conditions include but are not limited to History of HIV, Hepatitis B or C.
• Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
• Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Contacts and Locations

Locations

United States, California

William Sansum Diabetes Center

Santa Barbara, California, United States, 93105

Diablo Clinical Research

Walnut Creek, California, United States, 94598

United States, Idaho

Rocky Mountain Diabetes & Osteoporosis Center

Idaho Falls, Idaho, United States, 83404

United States, Washington

Rainier Clinical Research

Renton, Washington, United States, 98057

Sponsors and Collaborators

Abbott Diabetes Care

Investigators

• Study Director: Shridhara K Alva, PhD; Abbott Diabetes Care

More Information

• Responsible Party: Abbott Diabetes Care
• ClinicalTrials.gov Identifier: NCT03257501
• Other Study ID Numbers: ADC-US-VAL-17166
• First Posted: August 22, 2017
• Last Update Posted: January 9, 2018
• Last Verified: January 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes
• Product Manufactured in and Exported from the U.S.: No